Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
| Status: | Completed |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | July 2002 |
| End Date: | April 2008 |
Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors
The primary objective of the study was to define the safety profile and maximum tolerated
dose (MTD) of sorafenib tablets in combination with carboplatin and paclitaxel chemotherapy
in patients with advanced, refractory solid tumors.
The secondary objectives were evaluation of pharmacokinetics (PK) and tumor response of
these patients being treated with sorafenib in combination with paclitaxel and carboplatin.
dose (MTD) of sorafenib tablets in combination with carboplatin and paclitaxel chemotherapy
in patients with advanced, refractory solid tumors.
The secondary objectives were evaluation of pharmacokinetics (PK) and tumor response of
these patients being treated with sorafenib in combination with paclitaxel and carboplatin.
Inclusion Criteria:
- Histologically confirmed solid tumors
- Evaluable disease
- Eastern Cooperative Oncology Group (ECOG) 0 or 1
- Life expectancy minimum 12 weeks
Exclusion Criteria:
- Congestive heart failure
- Serious arrhythmias
- Coronary artery disease (CAD) or ischemia
- HIV (human immunodeficiency virus)
- Hepatitis B or C
- Serious active infection
- Metastatic brain or meningeal tumors
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials